Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter ...

Raiven Capital, a global early-stage venture capital firm, announced today that founding partner Paul Dugsin, will present “Investing in AI from a VC Perspective: Hype, Risk, and Return” at the DDC ...